Bevacizumab Against Recurrent Retinal Detachment
NCT02192970
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
101
Enrollment
OTHER
Sponsor class
Conditions
Retinal Detachment
Proliferative Vitreoretinopathy
Interventions
DRUG:
Bevacizumab
Sponsor
University of Wisconsin, Madison